The TGA is considering a proposal to reclassify psilocybin and MDMA from their current status as prohibited substances. This would allow psychiatrists to use these drugs to treat mental illness.
As the UK’s first clinic to offer psychedelic drugs for mental health disorders opens, a study reveals that informed users don’t have problems with self control.
Ketamine and other psychedelics are being licensed for medical use – two experts advise how to minimise harm for users.
Australia is about to start its first trial of psychedelic drugs for the treatment of anxiety and depression. If the results are positive, this could transform the way we treat mental illness.